# Hydralazine Versus Labetalol for the Management of Hypertensive Disorders of Pregnancy

Study · id `cardio:ct-nct01538875` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01538875](<https://clinicaltrials.gov/study/NCT01538875>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01538875

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 261 participants.

## Technical summary

Registry record NCT01538875. Randomized; no masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2013-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 261 participants (enrolled count; ClinicalTrials.gov record NCT01538875, source copy `cardio:ctgov-nct01538875-2013-05-17`, retrieved 2026-10-26)
- Start date: 2012-07 (registry gives no type) (ClinicalTrials.gov record NCT01538875, source copy `cardio:ctgov-nct01538875-2013-05-17`, retrieved 2026-10-26)
- Primary completion: 2013-04 (actual) (ClinicalTrials.gov record NCT01538875, source copy `cardio:ctgov-nct01538875-2013-05-17`, retrieved 2026-10-26)
- Completion: 2013-05 (actual) (ClinicalTrials.gov record NCT01538875, source copy `cardio:ctgov-nct01538875-2013-05-17`, retrieved 2026-10-26)
- Countries: Panama (ClinicalTrials.gov record NCT01538875, source copy `cardio:ctgov-nct01538875-2013-05-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01538875-2013-05-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Hydralazine Versus Labetalol for the Management of Hypertensive Disorders of Pregnancy
- Condition: Hypertension, Pregnancy Induced
- Intervention (Drug): Hydralazine
- Intervention (Drug): Labetalol
- Lead sponsor: Saint Thomas Hospital, Panama
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: 9e8225e172e411ca087fde9fa6d2de4596661eeea1be32f5fde7ee77e2eb2fb5
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
